




CD4+ T-cells

Figure S3. Manual gating strategy of spleen -derived leukocytes of naive, 4T1 tumor bearing and cisplatin treated 4T1 tumorous mice

Naive




4T1


4T1
+
cisplatin

CD8+ T-cells


Naive



4T1




4T1
+
cisplatin




CD19+ B-cells


Naive



4T1




4T1
+
cisplatin




CD11b+


Naive



4T1




4T1
+
cisplatin




CD11c+


Naive



4T1




4T1
+
cisplatin




MDSCs


Naive



4T1




4T1
+
cisplatin




CD44+ MDSCs


Naive



4T1




4T1 + cisplatin




IL-17A+ MDSCs


Naive



4T1




4T1
+
cisplatin




B220+ B-cells


Naive



4T1




4T1
+
cisplatin




CD62L+ B-cells


Naive



4T1




4T1
+
cisplatin




CD62L+ CD4+ T-cells


Naive



4T1




4T1
+
cisplatin




CD62L+ CD8+ T-cells

Naive



4T1



4T1
+
cisplatin

